Chronic Leg Ulcer

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Chronic Leg Ulcer is an early-stage landscape with 0 programs across 1 company. The most active players are Biotec Pharmacon ASA.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Biotec Pharmacon ASA

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Recruiting3 · 43%

Completed2 · 29%

Unknown status1 · 14%

Withdrawn1 · 14%

Clinical Trials

Trial Activity

7 trials

Efficacy of Platelet-rich-Fibrin Gel in Patients With Chronic Leg Ulcers

Recruiting·PPak Emirates Military Hospital·Phase 1·NCT07294521·40 enrolled

Topical Sevoflurane for Treatment of Chronic Leg Ulcers

Recruiting·—·Phase 4·NCT05303805·50 enrolled

Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers

Recruiting·—·Phase 1/2·NCT07048054·18 enrolled

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT01316796·28 enrolled

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

Completed·BBiotec Pharmacon ASA·Phase 2·NCT00288392·60 enrolled

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

Withdrawn·TTauTona Group·Phase 1/2·NCT04058197

Treatment of Chronic Leg Ulcers With Autologous Stromal Vascular Fraction

Unknown status·OOdense University Hospital·N/A·NCT02987101·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)